Published in Ophthalmology on September 19, 2010
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int (2015) 1.54
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol (2012) 1.47
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46
Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci (2014) 1.45
Interobserver agreement in detecting spectral-domain optical coherence tomography features of diabetic macular edema. PLoS One (2015) 1.39
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Ocular complications of diabetes mellitus. World J Diabetes (2015) 1.27
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ (2012) 1.17
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol (2013) 1.17
Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci (2013) 1.07
New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) (2012) 1.04
Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema. Biomed Opt Express (2015) 1.04
Diabetic retinopathy and VEGF. Open Ophthalmol J (2013) 1.03
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol (2013) 1.02
Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci (2014) 1.01
Short-term results of intravitreal dexamethasone implant (OZURDEX(®)) in treatment of recalcitrant diabetic macular edema: A case series. Oman J Ophthalmol (2012) 1.00
Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open (2013) 1.00
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest (2014) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Curr Diab Rep (2013) 0.99
Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther (2013) 0.97
Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm (2013) 0.97
Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95
Beyond AREDS: is there a place for antioxidant therapy in the prevention/treatment of eye disease? Invest Ophthalmol Vis Sci (2011) 0.93
Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev (2014) 0.91
Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology (2013) 0.90
Bevacizumab for the management of diabetic macular edema. World J Diabetes (2013) 0.90
Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol (2012) 0.90
Time required for navigated macular laser photocoagulation treatment with the Navilas. Graefes Arch Clin Exp Ophthalmol (2012) 0.90
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes (2013) 0.89
Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int (2014) 0.89
Ranibizumab in diabetic macular edema. World J Diabetes (2013) 0.89
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther (2013) 0.89
12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation. Br J Ophthalmol (2014) 0.88
The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy. Proteomics Clin Appl (2014) 0.88
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol (2011) 0.88
Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med (2014) 0.88
Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema. PLoS One (2015) 0.86
Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res (2012) 0.86
Recent developments in laser treatment of diabetic retinopathy. Middle East Afr J Ophthalmol (2015) 0.86
Novel pharmacotherapies in diabetic retinopathy. Middle East Afr J Ophthalmol (2015) 0.85
Targeting Neovascularization in Ischemic Retinopathy: Recent Advances. Expert Rev Ophthalmol (2013) 0.84
Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond) (2013) 0.84
The evolving treatment options for diabetic macular edema. Int J Inflam (2013) 0.83
Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes. Int J Mol Sci (2014) 0.82
Fluorescein angiography versus optical coherence tomography-guided planning for macular laser photocoagulation in diabetic macular edema. Retina (2014) 0.82
Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report. Indian J Ophthalmol (2012) 0.82
Bevacizumab and intraocular tumors: an intriguing paradox. Mol Vis (2012) 0.82
Prophylaxis of macular edema with intravitreal ranibizumab in patients with diabetic retinopathy after cataract surgery: a pilot study. J Ophthalmol (2011) 0.81
Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. Br J Clin Pharmacol (2012) 0.81
Intravitreal Corticosteroids in the Management of Diabetic Macular Edema. Curr Ophthalmol Rep (2013) 0.81
Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4). PLoS One (2013) 0.81
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) (2015) 0.81
Relationship between Outer Retinal Layers Thickness and Visual Acuity in Diabetic Macular Edema. Biomed Res Int (2015) 0.81
Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study). BMC Ophthalmol (2015) 0.80
Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. Clin Ophthalmol (2014) 0.80
Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med (2014) 0.80
Evolving strategies in the management of diabetic retinopathy. Middle East Afr J Ophthalmol (2013) 0.80
Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol (2015) 0.80
Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS One (2014) 0.80
Algorithm for the Measure of Vitreous Hyperreflective Foci in Optical Coherence Tomographic Scans of Patients With Diabetic Macular Edema. JAMA Ophthalmol (2016) 0.79
Laser-based strategies to treat diabetic macular edema: history and new promising therapies. J Ophthalmol (2014) 0.79
Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2014) 0.79
Future opportunities in diabetic retinopathy research. Curr Opin Endocrinol Diabetes Obes (2016) 0.78
Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol (2014) 0.78
Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci (2013) 0.78
Peripapillary nerve fiber layer thickness changes after macular photocoagulation for clinically significant diabetic macular edema. Saudi J Ophthalmol (2014) 0.78
Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Invest Ophthalmol Vis Sci (2013) 0.78
Diabetic macular edema: therapeutic options. Diabetes Ther (2012) 0.78
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. Drugs Aging (2014) 0.78
Enface Thickness Mapping and Reflectance Imaging of Retinal Layers in Diabetic Retinopathy. PLoS One (2015) 0.78
Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). Eye (Lond) (2015) 0.78
Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab. Eye (Lond) (2014) 0.78
A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol (2015) 0.78
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. Clinicoecon Outcomes Res (2012) 0.78
Randomised clinical trial evaluating best-corrected visual acuity and central macular thickness after 532-nm subthreshold laser grid photocoagulation treatment in diabetic macular oedema. Eye (Lond) (2015) 0.77
Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. J Ophthalmic Vis Res (2015) 0.77
Updates on the Clinical Trials in Diabetic Macular Edema. Middle East Afr J Ophthalmol (2016) 0.77
Combined therapy for diabetic macular edema. Middle East Afr J Ophthalmol (2013) 0.77
Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. Jpn J Ophthalmol (2016) 0.77
Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema. Int Ophthalmol (2013) 0.77
Outer photoreceptor layer thickness mapping in normal eyes and eyes with various macular diseases using spectral domain optical coherence tomography: a pilot study. Graefes Arch Clin Exp Ophthalmol (2013) 0.77
Combination therapy for diabetic macular edema. J Ophthalmol (2012) 0.77
Review of therapeutic advances in diabetic retinopathy. Ther Adv Endocrinol Metab (2011) 0.77
Triple therapy: Phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of bevacizumab for diffuse diabetic macular edema. Med Sci Monit (2012) 0.77
[Diabetic maculopathy]. Ophthalmologe (2015) 0.76
Current and future management of diabetic retinopathy: a personalized evidence-based approach. Diabetes Manag (Lond) (2013) 0.76
Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.76
Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography. Korean J Ophthalmol (2014) 0.76
Transconjunctival 25-gauge pars plana vitrectomy and internal limiting membrane peeling for chronic macular edema. Clin Ophthalmol (2012) 0.76
Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population. J Ophthalmic Vis Res (2016) 0.75
Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema. Clin Ophthalmol (2015) 0.75
Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema. J Curr Ophthalmol (2016) 0.75
Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol (2016) 0.75
The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes (2015) 0.75
Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center. Pak J Med Sci (2016) 0.75
The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in rats. Exp Eye Res (2015) 0.75
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.60
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology (2012) 3.35
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 3.34
The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol (2004) 2.89
Outcomes of 140 consecutive cases of 25-gauge transconjunctival surgery for posterior segment disease. Ophthalmology (2005) 2.85
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol (2011) 2.80
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther (2006) 2.59
Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A (2006) 2.57
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology (2012) 2.36
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol (2013) 2.32
Evaluation of patients with scleritis for systemic disease. Ophthalmology (2004) 2.22
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Chronic retinal necrosis: cytomegalovirus necrotizing retinitis associated with panretinal vasculopathy in non-HIV patients. Retina (2013) 2.12
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 2.07
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol (2006) 2.04
Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci (2002) 2.03
Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol (2007) 2.00
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology (2003) 1.96
Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest (2005) 1.92
Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol (2008) 1.89
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol (2009) 1.86
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology (2003) 1.83
Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology (2005) 1.80
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79
Recent trends in the management of rhegmatogenous retinal detachment. Surv Ophthalmol (2008) 1.78
Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes (2007) 1.77
Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol (2005) 1.73
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.71
Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol (2007) 1.70
New treatments for neovascular acute macular degeneration. BMJ (2007) 1.69
Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging. Retina (2012) 1.68
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68
Comparison of topical anesthetics for intravitreal injections : a randomized clinical trial. Retina (2012) 1.63
Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol (2009) 1.63
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology (2011) 1.62
Silicone oil retention sutures in aphakic eyes with iris loss. Arch Ophthalmol (2010) 1.62
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 1.59
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.58
Endothelial dystrophy, iris hypoplasia, congenital cataract, and stromal thinning (edict) syndrome maps to chromosome 15q22.1-q25.3. Am J Ophthalmol (2002) 1.56
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol (2013) 1.55
Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina (2010) 1.54
Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin Neurol Neurosurg (2008) 1.53
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
Central macular splaying and outer retinal thinning in asymptomatic sickle cell patients by spectral-domain optical coherence tomography. Am J Ophthalmol (2011) 1.51
Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol (2002) 1.50
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J (2007) 1.49
Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol (2002) 1.48
Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Retina (2003) 1.46
Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci (2014) 1.45
Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neurosci (2003) 1.44
Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol (2005) 1.43
Is coxsackievirus the cause of unilateral acute idiopathic maculopathy? Arch Ophthalmol (2004) 1.41
Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem (2004) 1.41
In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci (2007) 1.40
New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol Scand (2007) 1.40
Blood pressure control for diabetic retinopathy. Sao Paulo Med J (2015) 1.40
Lamina puncture for central retinal vein occlusion: results of a pilot trial. Arch Ophthalmol (2006) 1.39
Modification of silicone oil retention sutures in aphakic eyes with iris loss-reply;. Arch Ophthalmol (2012) 1.38
Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther (2009) 1.37
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J (2006) 1.35
Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol (2012) 1.35
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34
Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem (2007) 1.34
Preliminary 6 month results from the Argus II epiretinal prosthesis feasibility study. Conf Proc IEEE Eng Med Biol Soc (2009) 1.34
Identification of gene expression changes associated with the progression of retinal degeneration in the rd1 mouse. Invest Ophthalmol Vis Sci (2004) 1.33
Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology (2010) 1.32
Effects of different types of oxidative stress in RPE cells. J Cell Physiol (2006) 1.32
NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem (2009) 1.32
Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31